Strides Pharma Science Ltd News

This Mukul Agrawal portfolio pharma stock surged 12% in subdued market

Shares of Strides Pharma Science surged 12 per cent to Rs 736.05 on the BSE in Wednesday's intra-day trade in an otherwise subdued market

Strides Pharma rises 4% after NCLT nods creation of OneSource

Following this approval, OneSource will advance towards listing its equity shares on the BSE and NSE

Strides Pharma Q2 results: Net profit at Rs 93.7 cr, revenue up 20%

US revenue hitting quarterly high, sustained growth across markets among reasons

What's driven this Mukul Agrawal portfolio stock up 223% in 1 year; Details

Shares of Strides Pharma Science hit a new high of Rs 1,651.15, as they rallied 5 per cent on the BSE in Wednesday's intra-day trade in an otherwise a weak market

Strides Pharma CDMO arm gets Rs 801 cr from investors in pre-listing round

Strides Pharma Science on Wednesday said its associate firm has received equity commitment of Rs 801 crore from domestic and foreign institutional investors in the pre-listing round. OneSource Specialty Pharma, the contract development and manufacturing organisation (CDMO) arm of the company, has received confirmed capital infusion commitments from investors, Strides Pharma Science said in a statement. The share subscription agreements are being executed at a pre-money equity value of USD 1.65 billion, it added. The fundraise is in line with the scheme of arrangement announced in September 2023 and the investment is subject to customary closing conditions, including receipt of necessary regulatory approvals, the company said. "This fundraise will enable us to accelerate our growth plans, right-size our debt book, and commit significant new capex for a strong order book across our three platforms," Strides Group Founder Arun Kumar said. In September last year, Strides announced t

Strides Pharma Science gets USFDA nod for generic antidepressant tablets

Strides Pharma Science Ltd on Monday said its arm has received approval from the US health regulator for its generic version of antidepressant Fluoxetine tablets. The approval granted by the US Food & Drug Administration (USFDA) to wholly owned subsidiary Strides Pharma Global Pte. Ltd, Singapore, is for Fluoxetine tablets of strength 60 mg, Strides Pharma Science said in a regulatory filing. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine tablets, 60 mg, of TWi Pharmaceuticals, Inc, it added. The Fluoxetine tablets will be manufactured at the company's facility in Puducherry, Strides said. With the approval of the Fluoxetine Tabs 60 mg strength, the company is now positioned to offer a complete portfolio of Fluoxetine across capsules and tablets in 10 mg, 20 mg, and 60 mg strengths, it added. The addition of the Fluoxetine tablets 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of ...